General Electric Company (GE) 26.41 $GE
1 Stock to Invest in the Internet of Things
Motley Fool Staff - Motley Fool - Sat Nov 08, 8:05AM CST
There's been plenty of buzz around the Internet of Things, but it's difficult to find clear information about what it really means. Let's clear up that confusion. In the video below, you'll learn three things: We'll explain in plain English what...
TSLA: 240.20 (-1.02), SWIR: 33.90 (+0.30), AMZN: 299.86 (+3.22), GE: 26.41 (+0.05), EBAY: 53.51 (+0.25), QCOM: 69.26 (-1.32), GM: 31.59 (+0.22), GOOGL: 551.82 (+0.13), INTC: 33.58 (-0.24), GOOG: 541.01 (-1.03), AAPL: 109.01 (+0.31), CSCO: 25.33 (+0.07)
Facebook, Skyworks Among IBD 50's Top 5 Tech Earnings
at Investor's Business Daily - Sat Nov 08, 7:02AM CST
With earnings season starting to wind down, companies that reported excellent quarterly earnings growth, such as Faceboook, are likely candidates for a stock watch list. Today's IBD 50 list features five tech stocks that posted superior earnings...
GPRO: 79.06 (+0.30), GE: 26.41 (+0.05), EBAY: 53.51 (+0.25), SWKS: 59.88 (-2.26), ARRS: 30.84 (+0.35), FB: 75.60 (+0.34), GM: 31.59 (+0.22), TSM: 21.82 (+0.02), GOOGL: 551.82 (+0.13), NXPI: 73.54 (+0.07), INTC: 33.58 (-0.24), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)
Most active New York Stock Exchange-traded stocks
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 38.75 (+0.22), F: 14.17 (-0.02), GE: 26.41 (+0.05), RF: 10.16 (-0.07), ABX.TO: 13.79 (+0.82), K.TO: 2.84 (+0.30), ABX: 12.16 (+0.82), BAC: 17.36 (unch), ANR: 2.91 (+0.39), GNW: 8.41 (-0.25), YRI.TO: 4.47 (+0.44), KGC: 2.50 (+0.29), S: 4.72 (+0.03), TWTR: 40.31 (-0.53), AUY: 3.92 (+0.38)
Final Glance: Tools and Appliances companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top tools and appliances companies were mixed at the close of trading:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)
Charlene Begley Joins Red Hat's Board of Directors
Business Wire - Fri Nov 07, 3:05PM CST
Red Hat, Inc. (NYSE:RHT), the world's leading provider of open source solutions, today announced that Charlene Begley, a former executive at General Electric Company, has been appointed to the company's Board of Directors.
GE: 26.41 (+0.05), RHT: 61.30 (+0.56), WPPGY: 98.70 (+0.93), NDAQ: 43.88 (-0.02)
Middday Glance: Tools and Appliances companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 1 p.m.:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)
Skyworks Price Targets Up On Q4 Beat, Q1 Guidance
at Investor's Business Daily - Fri Nov 07, 11:40AM CST
Skyworks Solutions (SWKS) on Friday received six price target increases from analysts after the radio-frequency chipmaker's fiscal Q4 earnings report late Thursday easily topped Wall Street views. The Woburn, Mass.-based company's outlook for the...
GE: 26.41 (+0.05), SWKS: 59.88 (-2.26), TQNT: 22.07 (-0.82), GM: 31.59 (+0.22), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31), RFMD: 13.23 (-0.53)
Early Glance: Tools and Appliances companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 10 a.m.:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)
Aerospace Suppliers Ramping Up To Meet Surging Orders, Says GE Capital
Business Wire - Fri Nov 07, 7:00AM CST
The aerospace supply industry is still in the early days of a long-term boom in orders, say industry participants at a recent suppliers summit hosted by GE Capital at GE Aviation's headquarters in Cincinnati, OH. The large majority of participants, who were split about evenly in serving wide-body and narrow-body commercial aircraft platforms said they plan to increase their workforce over the next 12 months (84%), expect to win new long-term supply agreements in the next three years (91%), and expect aircraft deliveries to continue to grow at least through 2016 (76%).
GE: 26.41 (+0.05)
GE Antares Capital Finances Kohlberg & Company's Acquisition of PPC Industries, Inc.
Business Wire - Fri Nov 07, 7:00AM CST
GE Antares, a unit of GE Capital, announced today it is serving as administrative agent on a $160 million senior secured credit facility to support the acquisition of PPC Industries, Inc. by Kohlberg & Company. GE Capital Markets served as lead arranger and bookrunner on this facility.
GE: 26.41 (+0.05)
Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.41 (+0.05), SIAL: 135.34 (unch), MRK: 59.34 (+0.08), DHR: 81.19 (-0.07)
Southcross Holdings LP Announces $210 Million Capital Commitment from Energy Capital Partners and GE Energy Financial Services
Business Wire - Fri Nov 07, 6:00AM CST
Southcross Holdings LP ("Holdings"
announced today the completion of a $210 million preferred equity commitment from Energy Capital Partners Mezzanine Opportunities Fund and GE Energy Financial Services. Holdings owns 100% of Southcross Energy Partners GP, LLC, the general partner of Southcross Energy Partners, L.P. (NYSE:SXE) ("Southcross" , limited partner interests in Southcross, and several Eagle Ford based midstream assets.
GE: 26.41 (+0.05), SXE: 19.04 (+0.57)
GE Oil & Gas to invest USD60m in Lufkin, Texas foundry
M2 - Fri Nov 07, 5:40AM CST
GE Oil & Gas, a business division of GE (NYSE: GE) focused on the oil and gas industry, announced on Thursday plans to invest USD60m in expanding and modernising its foundry operations in Lufkin, Texas.
GE: 26.41 (+0.05)
Global Oligonucleotide Synthesis Market Outlook, 2019 - Product & Services, End-User & Application Analysis of the $1.7 Billion Industry
M2 - Fri Nov 07, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/2c8kv2/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019 The global oligonucleotide synthesis market is categorized on the basis of products and services, applications, end users, and geography. The synthesized oligonucleotides segment is expected to register the highest growth rate in the oligonucleotide synthesis market during the forecast period, owing to an increasing number of applications for synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos. Major factors contributing to growth of the oligonucleotide synthesis market include growing R&D expenditure in pharmaceutical and biotech companies; emerging applications of oligos in molecular diagnostics and synthetic biology; and evolving significance of RNA-interference oligos in therapeutics and diagnostics. Furthermore, government support and venture capital funding are other major factors that will boost the growth of this market. For instance, the U.S. National Institutes of Health (NIH) spend $1.5 billion per year to support their oligonucleotide-based applications. Further, in January 2013, Solstice Biologics, a South California start-up, raised $18 million in a series-A financing backed by venture capital funding for targeting and delivery of nucleic acid therapeutics. The relatively-untapped markets of the Asia-Pacific (APAC) region and the increasing R&D activities and funding there have opened up an array of opportunities for the oligonucleotide synthesis market. However, factors such as regulatory barriers, especially for therapeutic oligos, and downward pricing pressure may restrain the growth of this market. Scope of the Report Product & Services - Equipment - Reagent - Primer - Probe - Custom Oligos End-User - Research - Pharmaceutical & Biotechnology Application - Diagnostics - PCR - QPCR - Gene Synthesis - NGS - DNA - RNAi Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Oligonucleotide Synthesis Market By Products & Services 8 Global Oligonucleotide Synthesis Market, By Application 9 Global Oligonucleotide Synthesis Market, By End User 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2c...nucleotide
GE: 26.41 (+0.05), SIAL: 135.34 (unch)
General Electric's
at Investor's Business Daily - Thu Nov 06, 5:49PM CST
General Electric's (GE) oil and gas segment will invest $60 mil in improving its Lufkin, Texas-based foundry, which makes iron castings used in pumping units and power transmission equipment. The move comes amid GE's push to focus on its industrial...
GE: 26.41 (+0.05)
Skyworks Revenue Soars In Q4 As It Taps New Markets
at Investor's Business Daily - Thu Nov 06, 5:26PM CST
Skyworks Solutions late Thursday reported fiscal Q4 sales and earnings that handily beat Wall Street estimates, as did the company's outlook for the current quarter. Investors, however, apparently wanted more upside from the Apple (AAPL) supplier, as...
GPRO: 79.06 (+0.30), GE: 26.41 (+0.05), SWKS: 59.88 (-2.26), TQNT: 22.07 (-0.82), GM: 31.59 (+0.22), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31), RFMD: 13.23 (-0.53)
Look for Shares of General Electric to Potentially Pullback after Yesterday's 2.09% Rise
Comtex SmarTrend(R) - Thu Nov 06, 3:39PM CST
General Electric (NYSE:GE) traded in a range yesterday that spanned from a low of $25.87 to a high of $26.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $25.90 on volume of 40.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GE: 26.41 (+0.05)
After Yesterday's Rally of 2.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:39PM CST
General Electric (NYSE:GE) traded in a range yesterday that spanned from a low of $25.87 to a high of $26.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $25.90 on volume of 40.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GE: 26.41 (+0.05)
1 Stock to Invest in the Internet of Things
Motley Fool Staff - Motley Fool - Sat Nov 08, 8:05AM CST
There's been plenty of buzz around the Internet of Things, but it's difficult to find clear information about what it really means. Let's clear up that confusion. In the video below, you'll learn three things: We'll explain in plain English what...
TSLA: 240.20 (-1.02), SWIR: 33.90 (+0.30), AMZN: 299.86 (+3.22), GE: 26.41 (+0.05), EBAY: 53.51 (+0.25), QCOM: 69.26 (-1.32), GM: 31.59 (+0.22), GOOGL: 551.82 (+0.13), INTC: 33.58 (-0.24), GOOG: 541.01 (-1.03), AAPL: 109.01 (+0.31), CSCO: 25.33 (+0.07)
Facebook, Skyworks Among IBD 50's Top 5 Tech Earnings
at Investor's Business Daily - Sat Nov 08, 7:02AM CST
With earnings season starting to wind down, companies that reported excellent quarterly earnings growth, such as Faceboook, are likely candidates for a stock watch list. Today's IBD 50 list features five tech stocks that posted superior earnings...
GPRO: 79.06 (+0.30), GE: 26.41 (+0.05), EBAY: 53.51 (+0.25), SWKS: 59.88 (-2.26), ARRS: 30.84 (+0.35), FB: 75.60 (+0.34), GM: 31.59 (+0.22), TSM: 21.82 (+0.02), GOOGL: 551.82 (+0.13), NXPI: 73.54 (+0.07), INTC: 33.58 (-0.24), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)
Most active New York Stock Exchange-traded stocks
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 38.75 (+0.22), F: 14.17 (-0.02), GE: 26.41 (+0.05), RF: 10.16 (-0.07), ABX.TO: 13.79 (+0.82), K.TO: 2.84 (+0.30), ABX: 12.16 (+0.82), BAC: 17.36 (unch), ANR: 2.91 (+0.39), GNW: 8.41 (-0.25), YRI.TO: 4.47 (+0.44), KGC: 2.50 (+0.29), S: 4.72 (+0.03), TWTR: 40.31 (-0.53), AUY: 3.92 (+0.38)
Final Glance: Tools and Appliances companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top tools and appliances companies were mixed at the close of trading:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)
Charlene Begley Joins Red Hat's Board of Directors
Business Wire - Fri Nov 07, 3:05PM CST
Red Hat, Inc. (NYSE:RHT), the world's leading provider of open source solutions, today announced that Charlene Begley, a former executive at General Electric Company, has been appointed to the company's Board of Directors.
GE: 26.41 (+0.05), RHT: 61.30 (+0.56), WPPGY: 98.70 (+0.93), NDAQ: 43.88 (-0.02)
Middday Glance: Tools and Appliances companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 1 p.m.:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)
Skyworks Price Targets Up On Q4 Beat, Q1 Guidance
at Investor's Business Daily - Fri Nov 07, 11:40AM CST
Skyworks Solutions (SWKS) on Friday received six price target increases from analysts after the radio-frequency chipmaker's fiscal Q4 earnings report late Thursday easily topped Wall Street views. The Woburn, Mass.-based company's outlook for the...
GE: 26.41 (+0.05), SWKS: 59.88 (-2.26), TQNT: 22.07 (-0.82), GM: 31.59 (+0.22), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31), RFMD: 13.23 (-0.53)
Early Glance: Tools and Appliances companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top tools and appliances companies are mixed at 10 a.m.:
WHR: 175.81 (+0.97), GE: 26.41 (+0.05)
Aerospace Suppliers Ramping Up To Meet Surging Orders, Says GE Capital
Business Wire - Fri Nov 07, 7:00AM CST
The aerospace supply industry is still in the early days of a long-term boom in orders, say industry participants at a recent suppliers summit hosted by GE Capital at GE Aviation's headquarters in Cincinnati, OH. The large majority of participants, who were split about evenly in serving wide-body and narrow-body commercial aircraft platforms said they plan to increase their workforce over the next 12 months (84%), expect to win new long-term supply agreements in the next three years (91%), and expect aircraft deliveries to continue to grow at least through 2016 (76%).
GE: 26.41 (+0.05)
GE Antares Capital Finances Kohlberg & Company's Acquisition of PPC Industries, Inc.
Business Wire - Fri Nov 07, 7:00AM CST
GE Antares, a unit of GE Capital, announced today it is serving as administrative agent on a $160 million senior secured credit facility to support the acquisition of PPC Industries, Inc. by Kohlberg & Company. GE Capital Markets served as lead arranger and bookrunner on this facility.
GE: 26.41 (+0.05)
Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.41 (+0.05), SIAL: 135.34 (unch), MRK: 59.34 (+0.08), DHR: 81.19 (-0.07)
Southcross Holdings LP Announces $210 Million Capital Commitment from Energy Capital Partners and GE Energy Financial Services
Business Wire - Fri Nov 07, 6:00AM CST
Southcross Holdings LP ("Holdings"
announced today the completion of a $210 million preferred equity commitment from Energy Capital Partners Mezzanine Opportunities Fund and GE Energy Financial Services. Holdings owns 100% of Southcross Energy Partners GP, LLC, the general partner of Southcross Energy Partners, L.P. (NYSE:SXE) ("Southcross" , limited partner interests in Southcross, and several Eagle Ford based midstream assets. GE: 26.41 (+0.05), SXE: 19.04 (+0.57)
GE Oil & Gas to invest USD60m in Lufkin, Texas foundry
M2 - Fri Nov 07, 5:40AM CST
GE Oil & Gas, a business division of GE (NYSE: GE) focused on the oil and gas industry, announced on Thursday plans to invest USD60m in expanding and modernising its foundry operations in Lufkin, Texas.
GE: 26.41 (+0.05)
Global Oligonucleotide Synthesis Market Outlook, 2019 - Product & Services, End-User & Application Analysis of the $1.7 Billion Industry
M2 - Fri Nov 07, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/2c8kv2/oligonucleotide) has announced the addition of the "Oligonucleotide Synthesis Market by Product & Services, End-User , Application - Global Forecast to 2019" report to their offering. The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019 The global oligonucleotide synthesis market is categorized on the basis of products and services, applications, end users, and geography. The synthesized oligonucleotides segment is expected to register the highest growth rate in the oligonucleotide synthesis market during the forecast period, owing to an increasing number of applications for synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos. Major factors contributing to growth of the oligonucleotide synthesis market include growing R&D expenditure in pharmaceutical and biotech companies; emerging applications of oligos in molecular diagnostics and synthetic biology; and evolving significance of RNA-interference oligos in therapeutics and diagnostics. Furthermore, government support and venture capital funding are other major factors that will boost the growth of this market. For instance, the U.S. National Institutes of Health (NIH) spend $1.5 billion per year to support their oligonucleotide-based applications. Further, in January 2013, Solstice Biologics, a South California start-up, raised $18 million in a series-A financing backed by venture capital funding for targeting and delivery of nucleic acid therapeutics. The relatively-untapped markets of the Asia-Pacific (APAC) region and the increasing R&D activities and funding there have opened up an array of opportunities for the oligonucleotide synthesis market. However, factors such as regulatory barriers, especially for therapeutic oligos, and downward pricing pressure may restrain the growth of this market. Scope of the Report Product & Services - Equipment - Reagent - Primer - Probe - Custom Oligos End-User - Research - Pharmaceutical & Biotechnology Application - Diagnostics - PCR - QPCR - Gene Synthesis - NGS - DNA - RNAi Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Oligonucleotide Synthesis Market By Products & Services 8 Global Oligonucleotide Synthesis Market, By Application 9 Global Oligonucleotide Synthesis Market, By End User 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Bioautomation Corporation - Biosearch Technologies, Inc. - Eurofins Genomics (A Subsidiary of Eurofins Scientific Group) - Eurogentec (A Subsidiary of Kaneka Corporation) - GE Healthcare (A Subsidiary of General Electric Company) - Genedesign, Inc. - Integrated Dna Technologies - Sigma-Aldrich Corporation - Trilink Biotechnologies, Inc. - thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2c...nucleotide
GE: 26.41 (+0.05), SIAL: 135.34 (unch)
General Electric's
at Investor's Business Daily - Thu Nov 06, 5:49PM CST
General Electric's (GE) oil and gas segment will invest $60 mil in improving its Lufkin, Texas-based foundry, which makes iron castings used in pumping units and power transmission equipment. The move comes amid GE's push to focus on its industrial...
GE: 26.41 (+0.05)
Skyworks Revenue Soars In Q4 As It Taps New Markets
at Investor's Business Daily - Thu Nov 06, 5:26PM CST
Skyworks Solutions late Thursday reported fiscal Q4 sales and earnings that handily beat Wall Street estimates, as did the company's outlook for the current quarter. Investors, however, apparently wanted more upside from the Apple (AAPL) supplier, as...
GPRO: 79.06 (+0.30), GE: 26.41 (+0.05), SWKS: 59.88 (-2.26), TQNT: 22.07 (-0.82), GM: 31.59 (+0.22), COL: 84.80 (+0.82), AAPL: 109.01 (+0.31), RFMD: 13.23 (-0.53)
Look for Shares of General Electric to Potentially Pullback after Yesterday's 2.09% Rise
Comtex SmarTrend(R) - Thu Nov 06, 3:39PM CST
General Electric (NYSE:GE) traded in a range yesterday that spanned from a low of $25.87 to a high of $26.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $25.90 on volume of 40.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GE: 26.41 (+0.05)
After Yesterday's Rally of 2.09% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:39PM CST
General Electric (NYSE:GE) traded in a range yesterday that spanned from a low of $25.87 to a high of $26.39. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $25.90 on volume of 40.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GE: 26.41 (+0.05)
